TWI299732B - C10 ester substituted taxanes - Google Patents

C10 ester substituted taxanes Download PDF

Info

Publication number
TWI299732B
TWI299732B TW090102238A TW90102238A TWI299732B TW I299732 B TWI299732 B TW I299732B TW 090102238 A TW090102238 A TW 090102238A TW 90102238 A TW90102238 A TW 90102238A TW I299732 B TWI299732 B TW I299732B
Authority
TW
Taiwan
Prior art keywords
group
tbuoco
furyl
pharmaceutical composition
etcoo
Prior art date
Application number
TW090102238A
Other languages
English (en)
Chinese (zh)
Inventor
A Holton Robert
Original Assignee
Univ Florida State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida State Res Found filed Critical Univ Florida State Res Found
Application granted granted Critical
Publication of TWI299732B publication Critical patent/TWI299732B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00Containers or packages with special means for dispensing contents
    • B65D83/14Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
    • B65D83/75Aerosol containers not provided for in groups B65D83/16 - B65D83/74
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW090102238A 2000-02-02 2001-03-27 C10 ester substituted taxanes TWI299732B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17978200P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
TWI299732B true TWI299732B (en) 2008-08-11

Family

ID=22657972

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090102238A TWI299732B (en) 2000-02-02 2001-03-27 C10 ester substituted taxanes

Country Status (25)

Country Link
EP (1) EP1165553B1 (enExample)
JP (1) JP2003522172A (enExample)
CN (1) CN1380882A (enExample)
AT (1) ATE432928T1 (enExample)
AU (1) AU782150B2 (enExample)
BG (1) BG64889B1 (enExample)
BR (1) BR0104354A (enExample)
CA (1) CA2368274C (enExample)
CZ (1) CZ20013430A3 (enExample)
DE (1) DE60138853D1 (enExample)
GE (1) GEP20043323B (enExample)
HU (1) HUP0600302A2 (enExample)
IL (1) IL145638A (enExample)
MX (1) MXPA01009905A (enExample)
NO (1) NO327910B1 (enExample)
NZ (1) NZ514382A (enExample)
PL (1) PL202957B1 (enExample)
RO (1) RO121270B1 (enExample)
RU (1) RU2262506C2 (enExample)
SK (1) SK13692001A3 (enExample)
TR (1) TR200102858T1 (enExample)
TW (1) TWI299732B (enExample)
UA (1) UA75039C2 (enExample)
WO (1) WO2001057032A1 (enExample)
ZA (1) ZA200108055B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
CA2354471A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
SG129990A1 (en) * 2001-08-01 2007-03-20 Univ Florida State Res Found C10 ester substituted taxanes
SV2006002010A (es) 2004-02-13 2006-08-23 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
WO2006088767A2 (en) * 2005-02-14 2006-08-24 Florida State University Research Foundation, Inc. C10 cyclopropyl ester substituted taxane compositions
US8242166B2 (en) 2008-03-31 2012-08-14 Florida State University Research Foundation, Inc. C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5243045A (en) * 1991-09-23 1993-09-07 Florida State University Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5250683A (en) * 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
CA2158863C (en) * 1993-03-22 2006-12-19 Robert A. Holton Taxanes having a pyridyl substituted side-chain
EP0690711B1 (en) * 1993-03-22 2000-08-16 Florida State University Taxanes having an amino substituted side-chain
PT1228759E (pt) * 1993-03-22 2005-04-29 Univ Florida State Composicoes farmaceuticas contendo um taxano possuindo uma cadeia lateral substituida com furilo ou tienilo
US5475011A (en) * 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US6100411A (en) * 1994-10-28 2000-08-08 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
WO1996013495A1 (en) * 1994-10-28 1996-05-09 The Research Foundation Of State University Of New York Taxoid derivatives, their preparation and their use as antitumor agents
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AU758418B2 (en) * 1997-12-19 2003-03-20 Kabushiki Kaisha Yakult Honsha Taxane derivatives
JP2003026673A (ja) * 1999-03-05 2003-01-29 Asahi Kasei Corp 骨形成促進剤

Also Published As

Publication number Publication date
HUP0600302A2 (en) 2006-07-28
TR200102858T1 (tr) 2002-12-23
RU2262506C2 (ru) 2005-10-20
PL351380A1 (en) 2003-04-07
ATE432928T1 (de) 2009-06-15
BG64889B1 (bg) 2006-08-31
IL145638A (en) 2011-05-31
IL145638A0 (en) 2002-06-30
GEP20043323B (en) 2004-02-10
AU3480901A (en) 2001-08-14
SK13692001A3 (sk) 2002-07-02
NZ514382A (en) 2004-05-28
JP2003522172A (ja) 2003-07-22
EP1165553B1 (en) 2009-06-03
RO121270B1 (ro) 2007-02-28
PL202957B1 (pl) 2009-08-31
CZ20013430A3 (cs) 2002-04-17
BR0104354A (pt) 2002-01-02
EP1165553A1 (en) 2002-01-02
NO20014754D0 (no) 2001-10-01
AU782150B2 (en) 2005-07-07
BG105965A (en) 2002-07-31
UA75039C2 (en) 2006-03-15
NO327910B1 (no) 2009-10-19
NO20014754L (no) 2001-11-29
CN1380882A (zh) 2002-11-20
ZA200108055B (en) 2003-12-01
CA2368274C (en) 2009-10-13
CA2368274A1 (en) 2001-08-09
MXPA01009905A (es) 2003-08-20
DE60138853D1 (de) 2009-07-16
WO2001057032A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
TWI291873B (en) C7 ester substituted taxanes
TWI257390B (en) C10 heterosubstituted acetate taxanes
EP1040103B1 (en) Anilide derivative, production and use thereof
CN101978959B (zh) 含笑内酯及其衍生物用于治疗癌症的用途
CN105315321B (zh) 具有抗肿瘤作用的化合物及其制备方法和应用
CN102234259A (zh) 含笑内酯衍生物,其药物组合物及其制备方法和用途
Monserrat et al. Ferrocenyl flavonoid-induced morphological modifications of endothelial cells and cytotoxicity against B16 murine melanoma cells
TWI299732B (en) C10 ester substituted taxanes
Xue et al. Synthesis of taxol and docetaxel by using 10‐deacetyl‐7‐xylosyltaxanes
Wang et al. Design, synthesis, and biological evaluation of shikonin and alkannin derivatives as potential anticancer agents via a prodrug approach
CN109897022B (zh) 含笑内酯衍生物、其药物组合物及其制备方法和用途
CN110156822B (zh) 一种萘酚-苯硼酸类化合物及其制备方法和用途
CN101332198B (zh) 6-芳基-3-取代羰基吡啶类化合物的药物用途
CN107573327B (zh) 吲唑-甲酰胺-吡啶酮衍生物及其制备方法和用途
Tu et al. Synthesis and biological evaluation of 2′, 5′-dimethoxychalcone derivatives as microtubule-targeted anticancer agents
Bi et al. Synthesis and biological evaluation of 12-Np-chlorobenzyl sophoridinol derivatives as a novel family of anticancer agents
Cheng et al. Synthesis and biological evaluation of novel 9-functional heterocyclic coupled 7-deoxy-9-Dihydropaclitaxel analogue
Kumar et al. Caspase dependent apoptotic activity of polycyclic cage-like heterocyclic hybrids
EP3072896A1 (en) Taxane compound, and preparation method and use thereof
CN112661657B (zh) 一种舍曲林侧链氨基结构衍生物及其制备方法和应用
US10253007B2 (en) Taxanes compounds, preparation method therefor, and uses thereof
CN116785274A (zh) 大狼毒中具有强抗皮肤癌和抗炎活性的二萜化合物的制备方法和应用
CN106317175B (zh) 组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN103385865B (zh) 10-芳甲烯基蒽酮类化合物在制备抗肿瘤药物中的应用
CN110551080A (zh) 紫杉烷类化合物及其药物组合物和用途

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees